Journal of the American College of Surgeons · 2026
Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kesmodel Susan B, Lopez-Aguiar Alexandra, Grossman Julie, Zhao Wei, Koru-Sengul Tulay, Tang Jennifer, Nouri Keyvan, Hernandez-Aya Leonel, Lutzky Jose, Crystal Jessica S
Аннотация
BACKGROUND: Cutaneous squamous cell carcinoma (cSCC) often presents localized in the skin, but when it metastasizes to regional lymph nodes prognosis declines. Despite this, the role of sentinel lymph node biopsy (SLNB) in detecting metastasis is not well defined. This study uses the National Cancer Database (NCDB) to evaluate the role of SLNB in cSCC.
STUDY DESIGN: Patients with cSCC who underwent complete surgical excision (CSE) alone or CSE + SLNB were selected from the NCDB from 2012 to 2020. Overall survival (OS) in these cohorts was compared. Subgroup analyses of SLNB status and addition of completion lymph node dissection (CLND) were performed. Adjusted hazard ratio (HR) and 95% CI were calculated.
RESULTS: Of 2,730 patients, 42.3% underwent SLNB, and 15.4% had positive SLNB. Univariate survival analysis showed better OS in CSE + SLNB vs CSE alone (HR 0.85, 95% CI 0.74 to 0.98, p = 0.0253), and worse OS in SLNB-positive vs -negative patients (HR 2.82, 95% CI 2.22 to 3.58, p < 0.0001). In an adjusted survival model, better OS was associated with CSE + SLNB vs CSE alone (HR 0.70, 95% CI 0.59 to 0.82, p < 0.001), worse OS was associated with male sex, comorbid conditions, T2 or higher tumor, and lymphovascular invasion. Subgroup analysis of SLNB-positive patients showed no OS benefit with CLND (HR 0.63, 95% CI 0.30 to 1.33, p = 0.221).
CONCLUSIONS: An OS benefit was seen in patients who underwent SLNB, but not CLND. Although this may reflect a selection bias of the study population, given that a positive SLNB was associated with worse OS and new trials show survival benefit with the use of adjuvant therapies, future studies are needed to define the role of SLNB in patients with cSCC.
STUDY DESIGN: Patients with cSCC who underwent complete surgical excision (CSE) alone or CSE + SLNB were selected from the NCDB from 2012 to 2020. Overall survival (OS) in these cohorts was compared. Subgroup analyses of SLNB status and addition of completion lymph node dissection (CLND) were performed. Adjusted hazard ratio (HR) and 95% CI were calculated.
RESULTS: Of 2,730 patients, 42.3% underwent SLNB, and 15.4% had positive SLNB. Univariate survival analysis showed better OS in CSE + SLNB vs CSE alone (HR 0.85, 95% CI 0.74 to 0.98, p = 0.0253), and worse OS in SLNB-positive vs -negative patients (HR 2.82, 95% CI 2.22 to 3.58, p < 0.0001). In an adjusted survival model, better OS was associated with CSE + SLNB vs CSE alone (HR 0.70, 95% CI 0.59 to 0.82, p < 0.001), worse OS was associated with male sex, comorbid conditions, T2 or higher tumor, and lymphovascular invasion. Subgroup analysis of SLNB-positive patients showed no OS benefit with CLND (HR 0.63, 95% CI 0.30 to 1.33, p = 0.221).
CONCLUSIONS: An OS benefit was seen in patients who underwent SLNB, but not CLND. Although this may reflect a selection bias of the study population, given that a positive SLNB was associated with worse OS and new trials show survival benefit with the use of adjuvant therapies, future studies are needed to define the role of SLNB in patients with cSCC.